Osphos vs Red Light

Home >> Blog >> Osphos vs Red Light

Osphos vs Red Light Therapy: What One Horse Owner Tried Before Her Second Round of Injections

My vet said Osphos was the next logical step. I asked if there was anything I could try first. What happened over the next 8 weeks surprised me.

The morning ritual every older horse owner knows

My mare Olive’s first Osphos round worked. For about three months her short-stepping reduced. She moved more freely. Then it came back.

My vet was honest: “We can do another round. It should help again. But this is management, not resolution.”

I asked directly: is there anything that addresses the root cause? She paused. Then mentioned something I had not expected.

What bisphosphonates do and do not do

Osphos and Tildren are bisphosphonate drugs. They inhibit osteoclasts — the cells that break down bone. In navicular syndrome they slow bone remodeling and reduce pain. This is real and meaningful.

What bisphosphonates do not do is address the soft tissue and circulatory component. The laminae, navicular bursa, and DDFT depend on blood flow for health and repair. Bisphosphonates reduce pain. They do not restore circulation.

The underlying soft tissue degeneration continues in a lower-pain environment.

The medication manages the pain. The red light supports the tissue. They are doing different jobs.

Equine bodyworker · quoted during testing period

What red light addresses instead

Near-infrared 850nm light penetrates the hoof capsule and reaches the soft tissue structures directly — the digital cushion, the bursa, the connective tissue surrounding the navicular bone.

It stimulates the cells in those structures to produce more energy and increases local blood flow. It addresses the circulation component that pharmaceuticals do not reach.

The two approaches are not opposites. A horse on Osphos with daily red light therapy is addressing both components simultaneously. That is the protocol I moved to.

What 8 weeks of daily use showed

I added HaloLegs Mini morning and evening while delaying the second Osphos round. By week four, the morning hesitation was consistently shorter. By week six, the farrier noted improved hoof wall growth on the problem foot.

Four months later. We have not needed the second Osphos round yet. My vet told me to continue what I was doing and reassess in ninety days.

CRITERION	OSPHOS / BISPHOSPHONATES	HALOLEGs MINI
Addresses bone remodeling	Yes. Proven mechanism. FDA approved.	No. Does not affect osteoclast activity.
Addresses soft tissue circulation	No. Does not restore blood flow to laminae, bursa, or DDFT.	Yes. 850nm penetrates directly to soft tissue structures inside hoof.
Risk of side effects	Colic risk 30–45%. Kidney concerns with repeat use.	No known negative side effects. No withdrawal period.
Cost per cycle	$300–600 per injection. Repeated every 3–6 months.	One-time purchase. No ongoing costs.
Addresses overnight circulation loss	No. Single injection not tied to daily management.	Yes. Applied daily to address the 12-hour stall window.
Can be used together	Yes. Not mutually exclusive.	Yes. Addresses the component medication does not reach.

Equine Society verdict

Osphos is a proven pharmaceutical for navicular bone pain. The HaloLegs Mini targets the soft tissue and circulatory component that bisphosphonates do not address. For horses cycling through repeated injection rounds with temporary improvement followed by return of symptoms, daily red light therapy is the most logical addition to an existing management protocol. The two address different parts of the same condition.

★★★★★

Before your next injection round, try this for 30 days

4.9/5 from 61 verified owners. Used alongside existing navicular management. 30-day full refund guarantee.

30-day money-back guarantee · Free US shipping · No subscription